Pages that link to "Q33956146"
Jump to navigation
Jump to search
The following pages link to Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir (Q33956146):
Displaying 50 items.
- Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment (Q24803596) (← links)
- MinION: A Novel Tool for Predicting Drug Hypersensitivity? (Q26744637) (← links)
- Genetic Markers of the Host in Persons Living with HTLV-1, HIV and HCV Infections (Q26768628) (← links)
- Pharmacogenetics as a tool to tailor antiretroviral therapy: A review (Q26797938) (← links)
- Abacavir pharmacogenetics--from initial reports to standard of care (Q27008841) (← links)
- The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity (Q28080256) (← links)
- Genetic variations in HLA-B region and hypersensitivity reactions to abacavir (Q28214097) (← links)
- The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial (Q28256092) (← links)
- Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care (Q28546416) (← links)
- The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes (Q28610405) (← links)
- HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin (Q29417159) (← links)
- Determination of abacavir in human plasma by high-performance liquid chromatography with ultraviolet detection and the analytical error function. (Q33207117) (← links)
- Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial (Q33429155) (← links)
- HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review. (Q33666857) (← links)
- Abacavir/lamivudine combination in the treatment of HIV: a review. (Q33715435) (← links)
- HLA-B*5701 testing to predict abacavir hypersensitivity (Q33768961) (← links)
- High rate of loss to clinical follow up among African HIV-infected patients attending a London clinic: a retrospective analysis of a clinical cohort (Q34075017) (← links)
- Cardiac biomarkers in HIV-exposed uninfected children (Q34081675) (← links)
- Antiretroviral therapy: current drugs (Q34085926) (← links)
- Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir (Q34117815) (← links)
- Pharmacogenetics of drug hypersensitivity (Q34118186) (← links)
- Pharmacogenetics in clinical practice: considerations for testing (Q34499056) (← links)
- Genetic factors in the predisposition to drug-induced hypersensitivity reactions (Q34508545) (← links)
- A review of the pharmacokinetics of abacavir (Q34778565) (← links)
- Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection (Q34976284) (← links)
- Hypersensitivity reactions to HIV therapy (Q34976463) (← links)
- Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants (Q34982530) (← links)
- Tolerabilities of antiretrovirals in paediatric HIV infection. (Q34984835) (← links)
- The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. (Q35023687) (← links)
- A Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salerno (Q35023821) (← links)
- Critical illness in HIV-infected patients in the era of combination antiretroviral therapy (Q35095045) (← links)
- Early versus delayed antiretroviral therapy in patients with HIV infection : a review of the current guidelines from an immunological perspective (Q35162307) (← links)
- Frequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil (Q35179761) (← links)
- Genomics and Drug Response (Q35252277) (← links)
- Relaxation effect of abacavir on rat basilar arteries. (Q35597616) (← links)
- Pharmacogenetics to predict drug-related adverse events (Q35812477) (← links)
- HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury (Q35852627) (← links)
- Translational research in infectious disease: current paradigms and challenges ahead (Q35992621) (← links)
- Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing (Q36029478) (← links)
- Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics (Q36081993) (← links)
- Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients (Q36103159) (← links)
- Adversomics: a new paradigm for vaccine safety and design (Q36242667) (← links)
- A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study (Q36250418) (← links)
- Pharmacogenomics and drug development (Q36317013) (← links)
- Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection (Q36322100) (← links)
- Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again (Q36341730) (← links)
- The clinical implications of antiretroviral pharmacogenomics (Q36497078) (← links)
- Current therapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome (Q36546898) (← links)
- Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy (Q36651656) (← links)
- Abacavir/lamividune combination in the treatment of HIV-1 infection: a review (Q36675417) (← links)